{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:12:13Z","timestamp":1776737533710,"version":"3.51.2"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland GmbH","doi-asserted-by":"crossref","award":["n.a."],"award-info":[{"award-number":["n.a."]}],"id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec><jats:title>Background and aims:<\/jats:title><jats:p> To investigate effectiveness and safety of teriflunomide (14\u2009mg once daily) in association with age and pre-treatment in unselected MS patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Prespecified analysis of a non-interventional, prospective, real-world study in Germany. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> A total of 558 (49.5%) patients were above 45\u2009years old, and 593 patients (52.6%) had been pre-treated within 6\u2009months prior to teriflunomide. Baseline Expanded Disability Status Scale (EDSS) was higher with older age, with lower number of relapses. Relapse rate decreased in all age groups, and in both treatment-na\u00efve (0.82\u2009\u00b1\u20090.73 at baseline; 0.25\u2009\u00b1\u20090.55 under teriflunomide) and pre-treated (from 0.48\u2009\u00b1\u20090.76; 0.22\u2009\u00b1\u20090.50) patients after 12\u2009months compared with the year before teriflunomide initiation. EDSS remained stable in patients of all age groups as well as in therapy-na\u00efve and pre-treated patients over 24\u2009months. The percentage of patients with adverse events (AEs) ranged between 29.2% (age group &gt;25\u201335) and 38.9% (age group &gt;55\u201365), with an increased discontinuation rate (most commonly due to diarrhoea, alopecia and nausea) in the higher age groups. AE rates were lower in pre-treated compared with treatment-na\u00efve patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Overall, patients of all age groups including older patients, and irrespective of pre-treatment, benefit from teriflunomide treatment in routine clinical practice. <\/jats:p><\/jats:sec><jats:sec><jats:title>Registration:<\/jats:title><jats:p> BfArM public study database number 2075. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562864211005588","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T07:23:23Z","timestamp":1621322603000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status"],"prefix":"10.1177","volume":"14","author":[{"given":"Boris A.","family":"Kallmann","sequence":"first","affiliation":[{"name":"Multiple-Sclerosis-Center Bamberg, Bamberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Ries","sequence":"additional","affiliation":[{"name":"Neuro Centrum Odenwald, Erbach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Kullmann","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Quint","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-2681","authenticated-orcid":false,"given":"Ulrich","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Country MS Medical Head SGZ, Medical Affairs, Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, K703, 65926 Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bern University Hospital, University of Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"bibr1-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13536"},{"key":"bibr2-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13819"},{"key":"bibr3-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116773"},{"key":"bibr4-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.08.006"},{"key":"bibr5-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063172"},{"key":"bibr6-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101987"},{"key":"bibr7-17562864211005588","first-page":"84","volume":"68","author":"Fulop T","year":"2016","journal-title":"Rev Invest Clin"},{"key":"bibr8-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0771-9"},{"key":"bibr9-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0093-1"},{"key":"bibr10-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70056-X"},{"key":"bibr11-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000559"},{"key":"bibr12-17562864211005588","volume-title":"Aubagio [US prescribing information]","author":"Genzyme Corporation","year":"2020"},{"key":"bibr13-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00750-3"},{"key":"bibr14-17562864211005588","unstructured":"European Medicines Agency. Aubagio (Teriflunomide). European public assessment report. EMEA\/H\/C\/002514-N\/0015. Last update 13 December 2017, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002514\/WC500148682.pdf (2017, accessed 20 May 2020)."},{"key":"bibr15-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419835077"},{"key":"bibr16-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"bibr17-17562864211005588","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02247"},{"key":"bibr18-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0183-3"},{"key":"bibr19-17562864211005588","volume":"94","author":"Oh J","year":"2020","journal-title":"Neurology"},{"key":"bibr20-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320050"},{"key":"bibr21-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000057"},{"key":"bibr22-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-100"},{"key":"bibr23-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1159\/000447630"},{"key":"bibr24-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.10.002"},{"key":"bibr25-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512450354"},{"key":"bibr26-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000701"},{"key":"bibr27-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2003.008466"},{"key":"bibr28-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.171074"},{"key":"bibr29-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.237"},{"key":"bibr30-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1177\/1352458506070820"},{"key":"bibr31-17562864211005588","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh299"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864211005588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864211005588","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864211005588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:34:09Z","timestamp":1741001649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864211005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":31,"alternative-id":["10.1177\/17562864211005588"],"URL":"https:\/\/doi.org\/10.1177\/17562864211005588","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17562864211005588"}}